Precigen, Inc. PGEN
4.29 USD -0.01 (-0.23%)
Regular-session close
4.31 +0.02 +0.39%
After hours · Nov 17, 6:28 PM ET
4.19 Day range 4.35
3.04 52-week range 8.98
- YTD
- +2.63%
- 1 year
- -12.45%
News
benzinga.com B. Riley Securities Reiterates Buy on Precigen, Lowers Price Target to $11 B. Riley Securities analyst Yuan Zhi reiterates Precigen (NASDAQ:PGEN) with a Buy and lowers the price target from $12 to $11.
zacks.com What Makes Precigen (PGEN) a New Buy Stock Precigen (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com PGEN Q3 Earnings Call Highlights Launch Momentum and Competition Precigen's PAPZIMEOS launch gains traction with 37% sequential revenue growth, positive cash flow and expanding patient access as competition looms.benzinga.com Citizens Maintains Market Outperform on Precigen, Raises Price Target to $12 Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target from $11 to $12.
seekingalpha.com Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript
marketbeat.com What Precigen (PGEN) Said on Its Q3 Earnings Call Precigen NASDAQ: PGEN reported $72.9 million in third-quarter 2026 sales of PAPZIMEOS, its treatment for adults with recurrent respiratory papillomatosis, as the company posted a second consecutive…
zacks.com Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates Precigen, Inc. (PGEN) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.11 per share a year ago.
benzinga.com Precigen Q3 2026 Earnings Call Transcript Precigen (NASDAQ:PGEN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…benzinga.com Precigen Q3 EPS $0.08 Beats $0.07 Estimate, Sales $74.148M Beat $71.558M Estimate Precigen (NASDAQ:PGEN) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.07 by 14.29 percent. This is a 107.55 percent increase over losses of $(1.06) per…
prnewswire.com Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance PAPZIMEOS ® net revenue rose 37% quarter-over-quarter to $72.9 million in the third quarter of 2026 bringing launch-to-date net product revenue to $151 million, underscoring sustained commercial…
zacks.com Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect? PGEN's Q3 results hinge on Papzimeos sales momentum and pipeline updates as competitive threat grows from a newly approved RRP therapy.
benzinga.com Kosmos Energy Posts Downbeat Q3 Results, Joins Once Upon A Farm And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. futures rose, but Kosmos Energy plunged 13.6% after missing Q3 earnings and sales estimates; other stocks also fell in premarket trading.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
benzinga.com Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…
prnewswire.com Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4 GERMANTOWN, Md., Oct. 28, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve…
defenseworld.net Precigen, Inc. $PGEN Stock Sold by Iridian Asset Management LLC CT Iridian Asset Management LLC CT lowered its stake in Precigen, Inc. (NASDAQ: PGEN) by 24.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and…
defenseworld.net Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysis Precigen (NASDAQ: PGEN - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies…
zacks.com PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
defenseworld.net Comparing PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN) Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will contrast the two…
zacks.com 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
zacks.com Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase…
zacks.com PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
seekingalpha.com Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect Precigen just received an FDA "platform technology designation" for AdenoVerse, something that validates its versatility and accelerates its pipeline. PAPZIMEOS, the first FDA-approved product from…
zacks.com Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos? Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
defenseworld.net Precigen (NASDAQ:PGEN) Hits New 1-Year High – Time to Buy? Precigen, Inc. (NASDAQ: PGEN - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $8.04 and last traded at $7.89, with a volume of…
prnewswire.com Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq:…
defenseworld.net Head-To-Head Comparison: Precigen (NASDAQ:PGEN) and Celldex Therapeutics (NASDAQ:CLDX) Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Precigen (NASDAQ: PGEN - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two…
